Book Online or Call 1-855-SAUSALITO

Sign In  |  Register  |  About Sausalito  |  Contact Us

Sausalito, CA
September 01, 2020 1:41pm
7-Day Forecast | Traffic
  • Search Hotels in Sausalito

  • CHECK-IN:
  • CHECK-OUT:
  • ROOMS:

Halo Biosciences Participating in BIO @ JPM and BIOTECH SHOWCASE™ During J.P. Morgan Week 2022

SAN FRANCISCO - January 10, 2022 - (Newswire.com)

Halo Biosciences, a clinical stage biopharmaceutical company today announced that its Chief Executive Officer, Anissa Kalinowski, MSc, MBA, will present this week at the BIO@JPM and Biotech Showcase™ 2022 conferences.

At these events, the company will participate in virtual one-on-one meetings with registered participants and investors to introduce Halo Biosciences' business plans and to highlight the company's scientific advances and pipeline.

Event: BIO @ JPM
Date: January 10-14, 2022
Registration: https://www.bio.org/events/bio-partnering-jpm/registration

Event: Biotech Showcase 
Date: January 10-12, 17-19, 2022
Registration: https://informaconnect.com/biotech-showcase/registration-options

"At Halo Biosciences, we are advancing the development of an entirely new class of disease-modifying therapeutics that treat inflammatory and fibrotic diseases by targeting the extracellular matrix," says Anissa Kalinowski, CEO of Halo Biosciences. "Through our approach, we have a unique opportunity to address a number of chronic diseases with significant unmet need. We look forward to sharing our plans with potential collaborators and investors."

ABOUT HALO BIOSCIENCES

Halo Biosciences is a clinical stage biopharmaceutical company redefining the treatment of inflammatory and fibrotic diseases. Halo is developing a novel class of disease-modifying therapeutics that address underlying disease processes by editing the extracellular matrix (ECM). The company's lead compound, H01, specifically targets the dysregulation of hyaluronan (HA), a major component of the ECM, and a driver of edema, inflammation, and fibrosis. Following the successful completion of a Phase 1 study at Stanford University, H01 is now in development for the treatment of Group 3 pulmonary hypertension (PH).

Contact Information

Anissa Kalinowski

Chief Executive Officer

Telephone for media and investors: +1 650 308 8728

Email for media and investors: anissa@halobiosciences.com 

General inquiries: contactus@halobiosciences.com

Website: www.halobiosciences.com  

Follow Halo Biosciences on LinkedIn here




Press Release Service by Newswire.com

Original Source: Halo Biosciences Participating in BIO @ JPM and BIOTECH SHOWCASE™ During J.P. Morgan Week 2022
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.
 
 
Photos copyright by Jay Graham Photographer
Copyright © 2010-2020 Sausalito.com & California Media Partners, LLC. All rights reserved.